Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?

References

• Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-58
   PubMed Web of Science ®Google Scholar
• Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
   PubMed Web of Science ®Google Scholar
• Nagy JA, Chang SH, Dvorak AM, et al. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009;100:865-9
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47
   PubMed Web of Science ®Google Scholar
• Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 2002;277:11368-74
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474-88
   PubMed Web of Science ®Google Scholar
• Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl 5):10-17
   PubMedGoogle Scholar
• Ghosh S, Sullivan CA, Zerkowski MP, et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008;1835-43
   Google Scholar
• Skobe M, Rockwell P, Goldstein N, et al. Blocking angiogenesis results in tumor cell invasion suppression. Nat Med 1997;3:1222-7
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013;273:114-27
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768-78
   PubMed Web of Science ®Google Scholar
• vanHinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 2008;78:203-12
   Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011;47:2387-95
   PubMed Web of Science ®Google Scholar
• Robert NJ, Die´ras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93
   PubMed Web of Science ®Google Scholar
• Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and Breast Cancer: a Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol 2012;2012:417673
   PubMedGoogle Scholar
• Miles DW, Diéras V, Cortés J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013;24:2773-80
   PubMed Web of Science ®Google Scholar
• EMA. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d124 [Last accessed 12 December 2014]
   Google Scholar
• Roche. Available from: www.roche.com/media/media_releases/med-cor-2007-04-18b.htm [Last accessed 12 December 2014]
   Google Scholar
• Aogi K, Masuda N, Ohno S, et al. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011;129:829-38
   Google Scholar
• Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 2011;22:595-602
   PubMed Web of Science ®Google Scholar
• Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(12):1351-60
   PubMed Web of Science ®Google Scholar
• Lang I, Brodowicz T, Ryvo L, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013;14:125-33
   PubMed Web of Science ®Google Scholar
• Tredan O, Follana P, Moullet I, et al. Arobase: a phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV – A Gineco study. J Clin Oncol 2014;32:5s; suppl abstr 501
   Google Scholar
• Martin M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study. abstract S1-7 San Antonio Breast Cancer Symposium; 4–8 December, 2012; San Antonio, Texas, USA
   Google Scholar
• vonMinckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1269-78
   Google Scholar
• Gianni L, Romieu GH, Lichinitser M, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013;31:1719-25
   PubMed Web of Science ®Google Scholar
• vonMinckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299-309
   Google Scholar
• Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20
   PubMed Web of Science ®Google Scholar
• Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response rates in triple-negative breast cancer. abstract S5-01 Presented at San Antonio Breast Cancer Symposium 2013
   Google Scholar
• Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ±bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. abstract S1-03 Presented at 2013 San Antonio Breast Cancer Symposium
   Google Scholar
• Kümler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 2014;40:960-73
   PubMed Web of Science ®Google Scholar
• Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014; Epub ahead of print; 10.3978/j.issn.2305-5839.2014.08.14
   Google Scholar
• Eli Lilly and Company. A study of ramucirumab (IMC-1121B) in participants with breast cancer. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01256567 [Last accessed 13 November 2014]
   Google Scholar
• Yardley DA, Richards PD, Reeves JA, et al. Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). J Clin Oncol 2014;32(Suppl):abstract 1035
   Google Scholar
• Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 2014. [Epub ahead of print]; 10.1200/JCO.2014.57.1513
   Google Scholar
• Al-Halafi AM. Vascular endothelial growth factor trap-eye and trap technology: aflibercept from bench to bedside. Oman J Ophthalmol 2014;7:112-15
   Google Scholar
• Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008;7:3747-58
   PubMed Web of Science ®Google Scholar
• Sideras K, Dueck AC, Hobday TJ, et al. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer 2012;12:387-91
   Google Scholar
• Phase 1 Study testing the combination of aflibercept and capecitabine in metastatic digestive and breast cancers (MOMENTUM1). http://clinicaltrials.gov/show/NCT01843725 [Last accessed 13 November 2014]
   Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74
   PubMed Web of Science ®Google Scholar
• Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Christensen O, et al. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 2012;48:465-74
   Google Scholar
• Isaacs C, Herbolsheimer P, Liu MC, et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125:137-43
   PubMed Web of Science ®Google Scholar
• Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13:845-58
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-48
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chiorean EG, Verschraegen CF, et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010;28:4513-20
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
   PubMed Web of Science ®Google Scholar
• Yardley DA, Hart L, Bosserman L, et al. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat 2013;137:457-64
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2370-6
   PubMed Web of Science ®Google Scholar
• Wildiers H, Fontaine C, Vuylsteke P, et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:463-9
   PubMed Web of Science ®Google Scholar
• Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121-31
   PubMed Web of Science ®Google Scholar
• Crown JP, Diéras V, Staroslawska E, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013;31:2870-8
   PubMed Web of Science ®Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012;30:921-9
   PubMed Web of Science ®Google Scholar
• Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer 2011;47:277-86
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: north central cancer treatment group and mayo clinic trial N0336. J Clin Oncol 2009;27:11-15
   PubMed Web of Science ®Google Scholar
• Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24
   PubMed Web of Science ®Google Scholar
• Mina LA, Yu M, Johnson C, et al. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: hoosier Oncology Group Study BRE06-109. Invest New Drugs 2013;31:1307-10
   Google Scholar
• Puzanov I, Sosman J, Santoro A, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs 2014. [Epub ahead of print]; 10.1007/s10637-014-0167-5
   PubMedGoogle Scholar
• Fu X, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast 2013;22(Suppl 2):S12-18
   Google Scholar
• Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51
   PubMed Web of Science ®Google Scholar
• Awada A, Gil T, Whenham N, et al. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol 2011;51:1674-84
   PubMed Web of Science ®Google Scholar
• Mariani G, Burdaeva O, Roman L, et al. A double-blind, randomized phase lib study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer (MBC): FM-B07-01 trial. Eur J Cancer 2011;47(Suppl 2):10
   Google Scholar
• Schwartzberg LS, Tauer KW, Hermann RC, et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res 2013;19:2745-54
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Kaklamani V, Sahoo TP, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013;49:312-22
   PubMed Web of Science ®Google Scholar
• Baselga J, Segalla JG, Roché H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30:1484-91
   PubMed Web of Science ®Google Scholar
• Baselga J, Costa F, Gomez H, et al. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials 2013;14:228
   PubMed Web of Science ®Google Scholar
• Baselga J, Zamagni C, Gomez P, et al. A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE). Presented at European Society of Medical Oncology 2014
   Google Scholar
• Loibl S, Rokitta D, Conrad B, et al. Sorafenib in the treatment of early breast cancer: results of the neoadjuvant phase ii study-SOFIA. Breast Care 2014;9:169-74
   PubMed Web of Science ®Google Scholar
• Taylor SK, Chia S, Dent S, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010;15:810-18
   PubMed Web of Science ®Google Scholar
• Johnston SR, Gómez H, Stemmer SM, et al. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013;137:755-66
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Grazzini ML. Significant enhancements of anti-tumor efficacy of VEGF/PDGF RTK AG-013736 in combination with docetaxel in chemo-refractory and/or orthotopic xenograft tumor models in mice. Proc Am Assoc Cancer Res 2005;46: suppl; abstr 2032 475
   Google Scholar
• Rugo HS, Stopeck AT, Joy AA, et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011;29:2459-65
   PubMed Web of Science ®Google Scholar
• Hyams DM, Chan A, de Oliveira C, et al. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs 2013;31:1345-54
   PubMed Web of Science ®Google Scholar
• Clemons MJ, Cochrane B, Pond GR, et al. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat 2014;146:153-62
   PubMed Web of Science ®Google Scholar
• Boér K, Láng I, Llombart-Cussac A, et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs 2012;30:681-7
   PubMed Web of Science ®Google Scholar
• Martin M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011;12:369-76
   PubMed Web of Science ®Google Scholar
• Munoz R, Shaked Y, Bertolini F, et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005;14:466-79
   PubMed Web of Science ®Google Scholar
• Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006;17:232-8
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 2012;17:229-39
   Google Scholar
• Bernardi R, Gianni L. Hallmarks of triple negative breast cancer emerging at last? Cell Res 2014;24:904-5
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-52
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8. Erratum in: J Clin Oncol 2009;27:3070
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
   PubMed Web of Science ®Google Scholar
• Jiang X. Harnessing the immune system for the treatment of breast cancer. J Zhejiang Univ Sci B 2014;15:1-15
   Google Scholar
• A phase 1b study of MPDL3280A (an engineered anti-pdl1 antibody) in combination with avastin (bevacizumab) and/or with chemotherapy in patients with locally advanced or metastatic solid tumors. http://clinicaltrials.gov/show/NCT01633970 [Last accessed 13 November 2014]
   Google Scholar
• Montero AJ, Gluck S, Lopes GD. The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer. J Clin Oncol 2011;29; suppl; abstract 6060
   Google Scholar
• Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009;45:1397-406
   PubMed Web of Science ®Google Scholar